Sat, Apr 21, 2018
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Private Equity Strategies

MicroCap Monitor: DelMar Pharmaceuticals Highlights Continued Activity in Pharma at All Market Caps

Saturday, June 22, 2013

Bailey McCann, Private Equity Strategies

Founded in 2010, DelMar Pharmaceuticals is focused on clinical and commercial stage development of cancer treatment drugs. The company, which recently went public, has been talking to investors highlighting their clinical successes and pipeline projects. Co-Founder and CEO Jeffery Bacha and CFO Scott Praill recently spoke with Private Equity Strategies at the Marcum MicroCap Conference.

“We took the company public through an RTO in January, and it was generally positive,” explains Bacha. “Now we are focused on the trials and telling people our story.”

Unlike other cancer treatment companies, DelMar focuses on patients with on patients with refractory glioblastoma multiforme (GBM), the most common type of aggressive brain cancer. Treatment of this cancer has had mixed success although some drugs are showing promise where standard treatments have failed. Through clinical work in both the US and China, the company has already been awarded an Orphan Drug Designation by US FDA & European EMA for VAL- 083, one of its treatments for glioblastoma. The firm is working on clinical trials this year that look at the possibility of using higher doses of the drug in treatment for glioblastoma multiforme (GBM) and metastatic brain cancer for patients who have failed or are otherwise ineligible for currently approved treatments. This is big news for patients who are faced with a median survival of 4 months from diagnosis without treatment.

The team has been here before, they previously worked at another pharmaceutical firm, NCI on oncology treatments, and brought this knowledge to DelMar. The cancer treatment market as a segment of the broader pharmaceutical market is approximately $78bn. So far, DelMar’s story tracks with other companies in terms of successful IPOs, and positive shareholder value even through turbulent economic conditions.

According to a recent study of the global health care market for private equity by Bain Capital, deal value declined slightly in 2012, even while deal volume remained consistent. This indicator may point to broader interest in microcaps like DelMar. Interest from strategics is also on the rise making it harder for large private equity firms in the US and elsewhere to find deals and deploy capital efficiently.

The report shows that top returns in the health care market will likely come from “healthcare heavy” sectors, which reward risk taking and industry-specific expertise. 70% of the buyout deals done in this space in North America last year were done by small and midsize funds with some expertise in the field. “The implication: In order to unlock top-tier deal returns, funds are going to have to work harder and more creatively in North America to find assets, price them appropriately and create value post-close,” the report says.

Based on a recent analyst report of DelMar, these market factors could be a boon for the company, as they aren’t necessarily focused on acquisition. “We can control our own destiny,” Bacha says. “We have the capital available to us now through our IPO so we can after product revenue and we aren’t dependent on being acquired.”

That said, he notes that even if they sell, the team will probably look to repeat the process again around other products they already have in the pipeline. “The orphan disease market is more profitable than people think,” he says. “It takes skill, but there are a variety of opportunities for investors and companies here.”

 
This article was published in Opalesque's Private Equity Strategies our monthly research update on the global private equity landscape including all sectors and market caps.
Private Equity Strategies
Private Equity Strategies
Private Equity Strategies
Private Equity Strategies


Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Sequoia takes Facebook stake as shares slide in data controversy, $1.4b hedge fund sees intact fundamentals for Facebook, Jim Cramer reveals some 'suggested hedge fund trades' amid the Trump tariffs[more]

    Sequoia takes Facebook stake as shares slide in data controversy From Bloomberg.com: The $4.2 billion Sequoia Fund bought a small position in Facebook Inc. as the stock slid late in the first quarter, investment manager Ruane, Cunniff & Goldfarb told clients. "The recent controversy enab

  2. Activist Investors - Blue Sky-owned Wild Breads faces uncertain future[more]

    From AFR.com: A Blue Sky private equity investment in artisan-style baker Wild Breads enjoyed multiple valuation upgrades despite losing millions and breaching its lending covenants, accounts lodged with the regulator last week show. Wild Breads lost $2.4 million in 2017, but Blue Sky ascribed a hig

  3. Opalesque Exclusive: Barnegat to close hedge fund to outside investors on weak opportunities[more]

    Komfie Manalo, Opalesque Asia: Bob Treue's Barnegat Fund Management said it is closing its $666m fixed income relative value hedge fund to outside investors. "The negative side to gains in Fixed Income Arbitrage is that unless we find new opportunit

  4. Investing - Hedge fund makes a big bet on malls, British hedge fund manager Odey short UK government bonds on QE bet[more]

    Hedge fund makes a big bet on malls From Barrons.com: The dominant narrative on American shopping malls is that they're dead. Crushed by Amazon.com, many brick-and-mortar retail stores are destined for bankruptcy. And where is the most retail, clustered all together? Malls. From a

  5. Performance - Hedge funds suffer first back-to-back loss in two years, Netflix performance burns hedge fund short sellers, Macro hedge fund up 14.5% in first quarter sees dollar falling, Renaissance Technologies rebounds across hedge funds in March[more]

    Hedge funds suffer first back-to-back loss in two years From Bloomberg.com: Hedge Fund returns sank for a second straight month in March, the first back-to-back loss since the first two months of 2016, as trade wars, tech-sector woes and a Fed rate hike dragged down the S&P 500 from its